ScreenerHero
AVCNAvicanna Inc.
TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · avicanna.com
0.1350CAD+3.85%Mkt Cap: 12.37M $P/E: —

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmace…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap12.37M $
Enterprise Value18.59M $
Revenue (TTM)18.81M $
Gross Profit9.85M $
Net Income (TTM)-2.07M $
Revenue/Share0.1609 USD
Last Price0.1350 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees112
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA05368K1003
Valuation
P/E (Trailing)—
P/E (Forward)-2.25
PEG—
EV/EBITDA-9.67
EV/Revenue0.99
P/S0.66
P/B5.63
EPS (TTM)-0.02
EPS (Forward)-0.06
52W Range
0.095020% of range0.2980
52W High0.2980 CAD
52W Low0.0950 CAD
Profitability
Gross Margin53.06%
Oper. Margin-4.63%
EBITDA Margin-10.22%
Profit Margin-11.16%
ROE-100.02%
ROA-13.39%
Growth
Revenue Growth5.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-860.25K $
CapEx (TTM)186.34K $
FCF Margin-5.37%
FCF Yield-8.17%
Net Debt-270.99K $
Net Debt/EBITDA0.14
Balance Sheet
Debt/Equity0.00
Current Ratio0.96
Quick Ratio0.44
Book Value/Sh0.0240 CAD
Cash/Share0.0030 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.125.79M
Float109.95M
Insiders21.82%
Institutions0.00%
Short Interest
Short Ratio0.3d
Short % Out.0.03%
Shares Short62.18K
Short (prev mo.)80.96K
Technical
SMA 500.1262 (+7.0%)
SMA 2000.1710 (-21.0%)
Beta0.33
S&P 52W Chg18.16%
Avg Vol (30d)104.32K
Avg Vol (10d)70.68K
Technical Indicators
RSI (14)55.7
MACD0.0018
MACD Signal0.0010
MACD Hist.+0.0008
BB Upper0.1389 CAD
BB Middle0.1288 CAD
BB Lower0.1186 CAD
BB Width15.84%
ATR (14)0.0089 CAD
Vol Ratio (20d)1.91x